Posted inDermatology news Pediatrics
Breaking the Cycle of Chronic Wounds: Prademagene Zamikeracel Sets New Standard for RDEB Treatment
The Phase 3 VIITAL trial demonstrates that prademagene zamikeracel, an autologous gene-modified cellular sheet, significantly improves healing and reduces pain in patients with recessive dystrophic epidermolysis bullosa (RDEB), offering a transformative approach to managing large, chronic wounds.
